Stock Market Impact: SciSparc Ltd. (NASDAQ:SPRC) shares rose approximately 200% on Thursday following announcement of conditional regulatory approval for its subsidiary’s acquisition.
Listed Companies and Sectors: NeuroThera Labs Inc. (TSXV:NTLX), a subsidiary of SciSparc, received conditional approval from the TSX Venture Exchange to acquire about 54% of Israeli private company CliniQuantum Ltd., a quantum‑simulation technology firm serving clinical‑trial data analysis. The target holds an exclusive worldwide license with Quantum X Labs Ltd. for a U.S. provisional patent titled "Generating Quantum Markov Chain Monte Carlo Sampling Points for Continuous Distribution Functions."
Transaction Details: Under the share purchase agreement, NeuroThera will exchange 56,600,000 common shares for 56,375 ordinary shares of CliniQuantum, representing roughly 54% of CliniQuantum’s issued and outstanding shares. The consideration is valued at approximately US$9.5 million based on the 20‑day volume‑weighted average price of NeuroThera shares.
Closing Conditions & Amendments: On 30 April 2026 the parties amended the agreement, setting a floor price of US$0.05 per NeuroThera share for any earn‑out shares and extending the completion deadline from 30 April 2026 to 1 June 2026 to allow time for an Israeli tax ruling and final TSX acceptance.
Escrow Arrangement: The selling shareholders will place the 56,600,000 consideration shares into escrow pursuant to a Form 5D Escrow Agreement.
